Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Walleye Capital LLC boosted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 61.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 243,372 shares of the company's stock after acquiring an additional 92,552 shares during the period. Walleye Capital LLC owned about 0.47% of Spyre Therapeutics worth $7,158,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Amalgamated Bank acquired a new stake in shares of Spyre Therapeutics during the second quarter valued at $28,000. Quest Partners LLC acquired a new stake in shares of Spyre Therapeutics during the 2nd quarter worth about $36,000. SG Americas Securities LLC purchased a new stake in shares of Spyre Therapeutics during the second quarter worth about $130,000. Carlyle Group Inc. acquired a new position in shares of Spyre Therapeutics in the second quarter valued at approximately $227,000. Finally, Intech Investment Management LLC acquired a new position in shares of Spyre Therapeutics in the third quarter valued at approximately $246,000. Hedge funds and other institutional investors own 80.39% of the company's stock.

Spyre Therapeutics Price Performance

NASDAQ SYRE traded up $0.68 during mid-day trading on Friday, hitting $28.43. The company's stock had a trading volume of 211,487 shares, compared to its average volume of 717,818. The firm has a market capitalization of $1.46 billion, a P/E ratio of -3.81 and a beta of 2.90. Spyre Therapeutics, Inc. has a 52-week low of $14.22 and a 52-week high of $47.97. The stock's fifty day simple moving average is $31.07 and its two-hundred day simple moving average is $29.83.

Analyst Ratings Changes

SYRE has been the topic of a number of analyst reports. Guggenheim raised their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 25th. Wedbush restated an "outperform" rating and set a $45.00 price objective on shares of Spyre Therapeutics in a report on Friday, November 8th. Finally, Robert W. Baird upped their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Spyre Therapeutics presently has an average rating of "Buy" and an average target price of $48.57.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).